Cytopoint’s onset of action is a key consideration for veterinarians and pet owners managing canine pruritus (itching) associated with allergic or atopic dermatitis. The medication begins to alleviate itching sensations typically within 24 hours of administration. Individual responses, however, can vary slightly depending on the severity of the dog’s condition and individual physiological factors.
The relatively rapid action of this injectable medication offers significant advantages in managing canine allergic itch. Before its availability, managing such conditions often relied on corticosteroids or antihistamines, which can have broader systemic effects and potentially more significant side effects. Cytopoint targets a specific cytokine, IL-31, a key mediator of itch, thus providing a more targeted approach. This targeted approach contributes to reduced risk of widespread effects and allows for a potentially more comfortable experience for the dog.
